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Abstract 
Aim: To summarize healthcare costs incurred by patients with atrial fibrillation (AF) who developed 
ischemic stroke, explore factors associated with increased cost and highlight the importance of 
anticoagulation therapy for stroke prophylaxis.  
Methods: A systematic literature search of PubMed, EMBASE, Web of Science and the health 
economic evaluation database was conducted up to December 2015. Studies focused on the cost 
and/or resource utilization of ischemic stroke in patients with AF were included. Reported costs were 
converted to international dollars (I$) and adjusted to 2015 values. Alongside the narrative review of 
included studies, Spearman’s correlation, independent-samples t-test and one-way ANOVA were used 
to explore factors associated with cost differences between studies.  
Results: Sixteen studies published from nine countries were identified. Based on currency conversion 
rates in 2015, ischemic stroke related healthcare costs were estimated to be I$41,420, I$12,895 and 
I$8,184 for high-income, upper middle-income and lower middle-income economies respectively. 
Local GDP per capita accounted for approximately 50% of the healthcare cost variation among 
countries. Major component of overall cost was from hospitalization. Ischemic stroke incurring in 
patients with AF ≥75 years were 2.3 times that of their younger peers (p=0.049).  
Conclusions: The economic burden from ischemic stroke in patients with AF is considerable with 
positive association to country income. Clinicians and stakeholders should be aware of the importance 
of anticoagulation therapies in stroke prophylaxis, the occurrence of stroke and the downstream 
economic burden on an increasingly aging population. 
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Condensed abstract 
This systematic review estimated stroke-related healthcare cost across nine countries, with a positive 
correlation to country income. The cost for elderly patients’ ≥75 years was doubled against their 
younger peers. Adequate anticoagulation therapy for stroke prophylaxis and the downstream clinical 
and economic benefits in increasingly aging population are highlighted. 
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Introduction 
 Atrial fibrillation (AF) is the most common cardiac arrhythmia in 1-4% of adults worldwide, 
with prevalence increasing with age, affecting ≥13% of adults’ ≥80 years1. Importantly, AF is 
associated with an approximate five-fold increased risk of stroke and thromboembolism2. Age 
independently increases the risk of ischemic stroke with an adjusted hazard ratio per decade increase 
of 1.45 times (95%CI: 1.26-1.66) in patients with non-valvular AF (NVAF) 3. For patients ≤40 years 
old, only 1.9% suffered from ischemic stroke but this increased to 39-46% in elderly patients ≥80 
years4. The global aging population5, prevalence of AF and associated embolism stroke are expected 
to cause considerable disease and economic burden in forthcoming decades.  
 Patients with NVAF with CHA2DS2-VASc (Congestive heart failure/left ventricular 
dysfunction, hypertension, age ≥75 [doubled], diabetes mellitus, stroke [doubled]-vascular disease, 
age 65-74, and females) score ≥1 are recommended oral anticoagulants (OACs) for stroke 
prophylaxis2. Effective treatment options include warfarin (INR 2.0-3.0)6, dabigatran7, rivaroxaban8, 
apixaban9 or edoxaban10. The choice of anticoagulation therapy depends on the individual risk of 
stroke and bleeding as well as patients’ values and preferences2. Despite published guidelines, a 
substantial percentage of eligible patients are under-treated. A systematic review on the underuse of 
OACs revealed over two thirds of published studies reported relatively lower anticoagulation 
treatment levels (≤ 60%) among high-risk patients with NVAF11. In addition, there appears to be a 
tendency that the prescription rate among elderly patients is less likely to be adequate12. Thus 
improving the prescription rate of anticoagulation therapies is warranted, particularly with the aging 
population. 
The cost of AF has been reported in a published review of economic evaluations13.  However, 
the impact of ischemic stroke on AF related healthcare costs had not been researched at the time the 
study was conducted. Studies have been published in individual countries with diverse healthcare 
systems. Given the differences in reported currencies and cost components, all these heterogeneities 
limit the comparability between studies. In the present systematic review, we summarized ischemic 
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stroke related healthcare costs in patients with AF globally, explored the factors associated with 
increased cost, and highlighted the importance of stroke prophylaxis in the current situation of 
anticoagulation underuse and assessed the length of stay (LOS) in hospital to provide an indication of 
resource utilization.  
 
Methods 
Searching strategy 
The systematic literature search was conducted in January 2015 and updated in December 
2015 using four databases: PubMed, EMBASE, Web of Science and the Health Economic Evaluation 
Database (HEED). The search focused on original studies published in English from 1995 to 2015 
with available full-text. The keywords included the combination of the following terms and their 
medical subject headings including ‘cost,’ ‘atrial fibrillation’ and ‘stroke’. References cited in 
retrieved papers were also examined to identify any pertinent studies. Authors were contacted for 
further information if clarification was required after full-text digestion. PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses) guidelines14 were used as the basis for 
the literature search. 
Inclusion and exclusion criteria 
Studies were eligible if they focused on patients with AF and reported direct and/or indirect 
cost and/or hospital length of stay (LOS) in relation to ischemic stroke in those patients. Modeling 
cost or cost-effective analyses and studies that focused only on the healthcare cost of bleeding events 
were excluded. However, studies that explicitly mentioned ischemic stroke accounting for at least 70% 
of all stroke types (includes ischemic stroke, hemorrhagic stroke, unspecified stroke and transient 
ischemic attack) were included. 
 
6 
 
Data extraction 
Costs were converted into purchasing power parity (PPP) 2015 international dollars (I$) to 
increase comparability across countries, using the ‘CCEMG – EPPI-Centre Cost15. This adjusts 
estimates of cost expressed in one currency and price year to a specific target currency and price year. 
We chose the International Monetary Fund (IMF) dataset as the source for PPP values as opposed to 
Organization for Economic Co-operation and Development (OECD), as IMF covers more countries 
and currencies than OECD (183 vs. 30 countries)16, 17. 
Results were presented according to 2015 World Bank classification of economy income 
groups, based on gross national income (GNI) per capita in 201418. High-income economies (HIEs) 
are defined with a GNI per capita of $12,736 or more, middle-income economies (MIEs) are those 
with a GNI per capita of more than $1,045 but less than $12,736, low-income economies (LIEs) are 
those with a GNI per capita of $1,045 or less. Lower-middle-income economics (LMIEs) and upper-
middle-income economies (UMIEs) are separated at a GNI per capita of $4,125.  
Cost was also presented by different healthcare systems mainly according to the deductive 
classification by Katharina et al19.  The classification focused on the OECD countries and resulted in 
five types of healthcare systems based on different provision sectors for regulation, financing, and 
service in the health system. Healthcare systems for non-OECD members such as China, India and 
Taiwan (referenced from other publications20-22) were classified by the same criteria as per OECD 
countries. Types of healthcare systems, provision sectors, and country/region examples are presented 
in Table 1. 
Quality assessment methods 
Quality appraisal for the included cost analyses was based on a validated quality-scoring 
instrument of Quality Assessment for Health Economic Studies (QHES, Supplementary Table 1). 
The checklist of QHES contains 16 criteria with weighted scores from 0-9, emphasizing appropriate 
methods, valid and transparent results and comprehensive reporting of results for types of health 
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economic studies (score range=0-100; high quality≥75)23. As the present systematic review focused 
on real-world cost analysis rather than modeling cost-effective and health outcome research, two 
criteria (no. 11 and 12) relating to the health outcome measurement and modeling methods were not 
applicable in the quality assessment. With the omission of these two criteria, the quality scores ranged 
from 0 to 85, however, for the purposes of quality assessment, we maintained the ‘high quality’ score 
at ≥75. Two authors (XL and ADLW) screened the search results, crosschecked the retrieved data and 
assessed paper quality, with disagreements resolved through discussion. 
Statistical analysis 
The relationship between ischemic stroke related healthcare cost (presented as I$ 2015) and 
country GDP per capita in the same year was assessed by using Spearman’s correlation coefficient. 
To compare the costs of different age groups, two-tailed independent samples t-test was performed for 
age groups ≥75 and <75 years old. One-way ANOVA was conducted to explore variations of cost 
among different healthcare systems. Descriptive statistics was also performed for the summary of 
LOS. Mean [standard deviation (SD)] or median [interquartile range (IQR)] estimates were presented 
wherever appropriate. Sensitivity analysis was performed on the correlation analysis by removing data 
from developing countries. The statistical significance was set at p<0.05. All statistical analyses were 
conducted by IBM SPSS version 22.0. 
 
Results 
Paper Selection 
The literature search identified 1,530 records and two papers from the bibliographies of 
relevant review articles were added as pertinent studies. After removing duplicates, titles and abstracts 
from 954 papers were screened and 78 papers were eligible for full-text review (Figure 1).  Sixteen 
studies met the inclusion criteria for this systematic review (n=15 for cost analysis and n=10 for 
hospital LOS analysis). Of the 62 excluded papers, 15 papers explored all complications related to 
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costs although not all were specific to ischemic stroke and three papers presented only the cost or 
LOS differences. 
Study Characteristics 
Study characteristics of included studies indexed by alphabetical order of first author are 
summarized in Table 2. 
Publication year and regional distribution 
Studies were published between 2002 and 2015, with the majority between 2013 and 2014. 
Search results included studies from nine countries, with the majority of studies (n=7) conducted in 
Europe, followed by North America (n=5) and Asia (n=4). Regarding country income, 87.5% (n=14) 
of the studies were conducted in HIEs but only one study from LMIEs and UMIEs respectively. None 
of the studies were conducted in LIEs. 
Study design and data source 
Of the 16 included studies, there were seven prospective studies, eight retrospective studies 
and one cross-sectional study. Data sources were relatively balanced between hospital based (n=7) or 
registry (i.e. insurance or disease) based (n=9) studies. 
Perspective, time horizon and discounting rate 
In addition to different study objectives and data sources, the included studies also utilized 
different study perspectives (Figure 2-A).  Six studies adopted a payer or insurance perspective that 
was mainly conducted in the USA. Government/institutional perspectives and societal perspectives 
were adopted in four and five of the included studies, respectively. As reflected by the follow-up 
period in these studies, analytical time horizon ranged from one to five years (Table 2). 
Costing approaches 
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 The variation of costing approaches are illustrated in Figure 2-B. The most common method 
for cost estimation was a bottom-up approach (n=7) that summed-all unit costs accrued during 
management, treatment, hospitalization and follow-up of ischemic stroke. Insurance claim data were 
also used widely (n=4), although mainly in the USA. Top-down method was used only in two of the 
included studies in which disease-attributable costs were considered using a national reference of 
disease related group or hospital chart review. Two studies used a mixture of different costing 
approaches.  
Quality Assessment 
 The overall quality score of the 15 cost analyses was modest to high ranging from 49 to 85 
(mean ± SD: 68.7±9.9). The quality of individual papers is shown in Table 2 and the assessment 
details are provided in Supplementary Table 1. Cost data were all collected from a sample of patients 
with the sample size ranging from 23 to 23,807 (Table 2). As shown in Supplementary Table 1, all  
the studies provided clear information on the best available data source and methodology for data 
extraction. Of the included studies, fourteen studies (93%) stated well-justified limitations and 
conclusions and thirteen (86%) studies specified measurable objectives and utilized statistical model 
to address random effects. However, six studies (40%) stated the justifications for the chosen study 
perspective and only two studies (13.3%) justified discounting rate (3-5%) when time horizon was 
beyond one year. Incremental analysis for resources and costs were performed in nine (60%) of the 
included papers. 
Healthcare Cost  
Ischemic stroke related costs in patients with AF are summarized in Table 3 by country 
income groups. Original and converted cost details from individual studies are provided in 
Supplementary Table 2. As shown in Table 3, direct costs were reported across all of the 15 studies. 
Only three studies considered indirect costs although these accounted for only a small proportion of 
the total costs. Total costs were 3-5 times higher in HIEs than other economies (HIEs: I$41,420, 
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UMIE: I$12,895 and LMIE I$8,184). Mean total healthcare cost was estimated to be I$37,302 (SD: 
21,078) per patient based on PPP values of 2015 across all income groups. 
Costing components 
 Seven studies reported cost components for the direct cost estimation (Figure 3). Different 
cost components, including costs related to hospitalization, readmission, rehabilitation, emergency 
care, outpatient care, nursing care, healthcare visits, home/community healthcare and prescribed 
medications were considered in these studies. Inpatient costs accounted for the greatest proportion of 
total direct cost, ranging from 42.8% to 75.5%.  
Correlation of total direct cost and GDP per capita 
  Direct costs incurred by ischemic stroke was positively correlated with GDP per capita in the 
same year among all countries (Figure 4-A, Spearman’s correlation coefficient=0.64, p=0.01).  At the 
upper and lower limits of the reported costs, the cost per patient was 8.8 times greater in the USA 
(I$72,341) than in India (I$8,184). Overall, current local GDP per capita in 2015 can account for 
about 50% of the variation in direct cost estimates between countries (r2=0.338 in Figure 4-B). The 
sensitivity analysis showed similar results but had marginally failed to reach statistical significance 
(Figure 4-B, Spearman’s correlation coefficient=0.54, p=0.057).  
Cost differences between age groups 
 Fourteen included studies reported patients’ age at the time of recruitment (Table 2). The 
mean age of patients was 74.1±8.0 years and 60% of the studies focused on elderly patients aged 75 
years or above. Ischemic stroke related costs were compared between age groups with an age cut-off 
of 75 years old. Among AF patients with a history of ischemic stroke, healthcare costs for elderly ≥75 
years was 2.3 times that of the younger age group below 75 years (I$45,622 vs I$20,015, p=0.049).  
Cost differences among healthcare systems 
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No statistically significant cost difference was found among different healthcare systems 
(p=0.079) using ANOVA, possibly due to the limited sample size in each group (Figure 5). 
Regarding countries with existing healthcare systems (n=14, except for China and India where the 
healthcare systems are developing), the lowest direct cost estimates were the National Health Service 
in UK and Finland (I$27,451) and the highest was from the Private Health System in the USA 
(I$56,039). The trend suggests that the more private sectors are involved in the healthcare system, the 
higher the cost estimate. 
Impact of ischemic stroke on healthcare cost of AF 
 Four studies reported on the cost differences between patients with AF only compared to 
those with AF and history of ischemic stroke (Table 4). As reported from these studies, the total 
healthcare cost of patients with AF increased by 31-187% on occurrence of ischemic stroke. 
Hospital Lengths of Stay 
 Ten studies reported the median and/or mean LOS in hospital for the treatment of ischemic 
stroke (Supplementary Table 2). The median LOS estimate reported from these studies was 15.5 days 
per episode. The longest median LOS of 21 days (IQR: 60 days) was in Ireland24, while  an average 
LOS of 5.2 days for non-repeated stroke admissions and 6.8 days for repeated stroke admission in the 
USA were reported as the shortest25 among the included studies.  
 
Discussion 
 This systematic review captured 16 studies of ischemic stroke relevant costs and resource 
utilization in patients with AF from nine countries. The costs varied substantially with respect to 
differences in costing approaches, country income levels and healthcare systems. By converting 
reported costs into 2015 international dollars, an average treatment cost for ischemic stroke was 
estimated to be I$37,302 per patient globally and a positive correlation was found between the cost 
12 
 
and local GDP per capita. Interestingly, the sensitivity analysis showed that the correlation result was 
affected by China and India. As developing countries, the average GDP of China and India are much 
lower than other countries included in this review. Consequently, direct costs incurred by ischemic 
stroke per patient are also much lower than other included countries. There is urgent need for 
developing countries such as China and India to develop more integrated and efficient healthcare 
systems, which will minimize risk factors for stroke, such as effective use of anticoagulation 
therapies26-27 and smoking cessation strategies28.  
Another interesting point is the time horizon effect of the medical costs. Mercaldi et al 
(2012)55 was the only study which provided the details of costing components of ischemic stroke in 
the first three years. Their results showed that the costs of ischemic stroke in patients with AF were 
the highest in first year. The authors referred to the recurrence rate of ischemic stroke as a possible 
reason for the differences in the costs in different years. In addition, Mercaldi et al (2013)54 provided 
an estimation of the costs of ischemic stroke in patients with AF in Quarters 1 to 4.  They found that 
the costs decreased by nearly half from Quarter 1 ($23,334) to Quarter 2 ($12,761) and then stabilized 
in Quarters 3 ($7,074) and 4 ($6,750). However, the authors did not address either the reason behind it 
or the details of costing components.  
Elderly patients above 75 years of age cost more than twice as much as their younger peers 
below 75 years, possibly due to increased risk of complications29 resulting in prolonged LOS in 
hospital30. To our knowledge, this is the only study that has comprehensively quantified the economic 
impact of ischemic stroke in patients with AF across different countries. The main implication of this 
study is to highlight the importance of minimizing stroke risk using anticoagulation therapies in 
patients with AF. 
Gaps in standards of care for the diagnosis and management of AF are widely reported in 
both clinical trial31 and real-life settings32-34. It is estimated that 10-30% of AF are not diagnosed32, 35 
and more than 40% of patients at high risk of stroke fail to receive guideline-recommended oral 
anticoagulant treatment11, 35. The level of treatment varied among regions and study settings, ranging 
13 
 
from 19% in a prospective survey in a teaching hospital in Italy36 to 81% in an analysis of a national 
survey database in the USA37. Further, ensuring patients at high risk receive the most effective 
anticoagulation treatment remains a challenge. Although novel anticoagulants have been available 
since 2009, warfarin is still widely used, especially in the elderly and high-risk patients33, 38 with 
inadequate quality control39 and increased risk of stroke40, 41. All these gaps highlight unmet needs for 
stroke prevention in undiagnosed and undertreated AF, which will shed light on the strategies needed 
to eliminate disparities in treatment. 
 Consistent with previous published cost of illness of atrial fibrillation13, hospitalization cost 
for the treatment of stroke was the major driver of overall cost in this review. Our study found that the 
median LOS in hospitals for stroke patients with AF was estimated to be 15.5 days. From a healthcare 
resource utilization perspective, this economic burden and resource consumption may be reduced or 
avoided if sufficient anticoagulation care is provided to prevent stroke. Hence, it is important for 
clinicians and stakeholders to focus efforts to improve stroke prevention in patients with AF. 
 It is not unexpected that costs are significantly higher for elderly patients compared with 
younger patients and this is expected to increase markedly over future decades due to the ageing 
population globally42. Another interesting finding of this study is the trend of increased costs 
associated with more private sector involvement in the healthcare system. It is beyond the scope of 
our current study to explore the underlying reasons for this phenomenon. Faced with the increased 
healthcare burden and costs arising from the ageing population, countries around the globe need an 
integrated and efficient healthcare system to better meet the needs of these challenges. Healthcare 
system reform and redesign cannot be avoided, perhaps more so for those with private sector 
involvement. 
There are several limitations in this systematic review. First, only studies published in English 
were included which would introduce language and publication bias. Notably, a considerable 
proportion of the included studies were hospital-based using questionnaire interviews for costing43-45, 
which relied on self-reported data that may lead to selection and recall bias. Second, the quality of 
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published studies was variable. Only two of the 15 studies discounted the cost at certain rates, 
therefore the reported cost may not be an accurate reflection of actual cost. Indirect costs were only 
reported in a small proportion of studies24, 44, 45, which would hinder the overall cost estimation 
required for an assessment from the societal perspective. For labor market outcomes, the lack of 
research on the relevant costs of productivity loss44, 45 is also apparent. Ischemic stroke related 
healthcare costs are less clear from LIEs compared with HIEs. However, LIEs specifically involve 
countries with increasing AF prevalence and rapidly ageing populations where healthcare costs are 
particularly likely to escalate. Third, is the issue of time horizon, which may have an impact on 
medical costs. Of the 16 included studies, 15 reported on medical costs. Only 2 of these studies had 
specified the costs at various different time horizons but insufficient information was provided for 
further analysis. Due to the limited information provided in the reviewed studies, it is difficult to 
further explore the relationship between medical costs and time horizon. Lastly, compared with other 
costs of illness systematic reviews for AF13 and other diseases46, 47, this review included a smaller 
number of studies. However the sample size of the included studies was considered adequate. In 
general, current research on the economic burden of patients with AF with a history of ischemic 
stroke is inadequate in both quality and quantity. A standardized approach is imperative to enable fair 
comparisons across different countries. Despite the limitations, this review provided an overview of 
stroke related cost in patients with AF and estimated the cost ranges across countries of different 
incomes with greater certainty than individual studies. 
In summary, a considerable economic burden caused by ischemic stroke in patients with AF 
is consistently reported, especially in the elderly population. Increased costs are positively associated 
with the income level of the individual country. Stakeholders should recognize the importance of 
anticoagulation therapies in stroke prophylaxis and allocate sufficient resources to improve the 
prognosis of AF and thereby reduce the associated downstream economic burden. In addition, high 
quality studies are required to form the basis for long-term economic evaluation, particularly for less 
developed countries. 
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Table 1. Healthcare systems and relevant countries/regions 
Healthcare systems  Regulation  Finance  Service Countries/regions 
National health service State* State* State* UK, Finland 
National health insurance State* State* Private*** Ireland, Taiwan 
Etatist social health insurance State* Societal** Private*** France 
Social health insurance Societal** Societal** Private*** Germany 
Private health system Private*** Private*** Private*** USA 
Healthcare system under developing NA NA NA China, India 
* State sector: government; ** Societal sectors: private non-profit providers including but not limited to 
social security funds; *** Private sectors: private for-profit providers including but not limited to 
private insurances, tax financing and out-of-pocket expenditure. 
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Table 2. Study characteristics 
Study 
no. 
Reference Country and 
income groups 
Healthcare 
system 
Study design Sample 
size and 
patient age 
(years) 
Data 
source  
Perspective Time 
horizon  
Discounting 
rate 
Costing 
approach 
QHES 
score 
1 Ali N 201548 UK, High-
income 
economy 
National 
Health 
Service19 
Prospective 
cohort  
 
n=73; 
80.1±10.1 
 
Hospital 
based 
 
Institutional 
(unspecified) 
1 year 
 
Unspecified Bottom-up 
approach* 
59 
2 Brüggenjürgen 
200744 
 
Germany, 
High-income 
economy 
Social 
Health 
Insurance19 
Prospective 
cohort 
 
n=71; 
73.7±9.4  
Hospital 
based 
 
Societal 
(unspecified) 
 
1 year 
  
Unspecified Bottom-up 
approach* 
68 
3 Chang 200249 
 
Taiwan, High-
income 
economy 
National 
Health 
Insurance 20 
Single-arm 
prospective  
n=23; 
64.3±12.5 
Hospital 
based 
NA NA NA NA NA 
4 Cotte 201450 
 
France, High-
income 
economy 
Etatist Social 
Health 
Insurance19 
Retrospective 
cohort   
n=1,257; 
78.8±9.8 
 
Registry  
based  
Insurance  2 years Unspecified Top-down 
approach** 
59 
5 Fitch 201451 USA, High- Private Retrospective n=261; Registry Payer 1 year Unspecified Insurance 72 
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Study 
no. 
Reference Country and 
income groups 
Healthcare 
system 
Study design Sample 
size and 
patient age 
(years) 
Data 
source  
Perspective Time 
horizon  
Discounting 
rate 
Costing 
approach 
QHES 
score 
 income 
economy 
Health 
System 19 
cohort  83.5±8 based  (Medicare) 
(unspecified) 
claim data 
6 Hannon 
201424 
 
Ireland, High-
income 
economy 
National 
Health 
Insurance 19 
Single-arm 
prospective  
n=177; 
76.5 ± 10.5 
Registry 
based   
Societal  2 years Unspecified Mixed 
approach*** 
72 
7 Hu 201345 China, 
Upper-middle 
income 
economy 
NA Single-arm 
retrospective  
n=73; 
69.9±10.3 
 
Hospital 
based 
Societal  1 year  Undiscounted Bottom-up 
approach*  
66 
8 Huang 201352  
 
Taiwan, 
High-income 
economy 
National 
Health 
Insurance 20 
Cross-
sectional  
n=1,021; 
68.1±10.8 
 
 
Hospital 
based 
Government 
(unspecified) 
Unspecified  Unspecified Bottom-up 
approach*  
49 
9 Luengo- UK, National Single-arm n=153; Registry Institutional 5 years Unspecified Bottom-up 55 
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Study 
no. 
Reference Country and 
income groups 
Healthcare 
system 
Study design Sample 
size and 
patient age 
(years) 
Data 
source  
Perspective Time 
horizon  
Discounting 
rate 
Costing 
approach 
QHES 
score 
Fernandez 
201353  
High-income 
economy 
Health 
Service19 
prospective  80±10 
 
based  (unspecified) approach*  
10 Marfatia 
201443 
India, 
Lower-middle 
income 
economy 
NA Single-arm 
prospective  
n=400; 
61.4±9.4 
 
Hospital 
based 
Societal  1 year Unspecified Bottom-up 
approach*  
74 
11 Mercaldi 
201154 
 
USA, High-
income 
economy 
Private 
Health 
System 19 
Retrospective 
cohort  
n=119,764; 
79.3±8.6 
 
Registry 
based  
Payer 
(Medicare) 
(unspecified) 
1 year Unspecified Insurance 
claim data 
81 
12 Mercaldi 
201255 
 
USA, High-
income 
economy 
Private 
Health 
System 19 
Retrospective 
cohort 
(matched) 
n=7,799; 
81.1±7.6 
 
Population 
based  
Payer 
(Medicare)  
3 years Unspecified Insurance 
claim data 
78 
13 Meretoja 
201156 
Finland, High-
income 
National 
Health 
Retrospective 
cohort  
n=1,306; 
Age 
Registry 
based  
Societal  5 years 5% per year Mixed 
approach*** 
85 
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Study 
no. 
Reference Country and 
income groups 
Healthcare 
system 
Study design Sample 
size and 
patient age 
(years) 
Data 
source  
Perspective Time 
horizon  
Discounting 
rate 
Costing 
approach 
QHES 
score 
economy Service 19 unspecified 
14 Sussman 
201357 
USA, High-
income 
economy 
Private 
Health 
System 19 
Retrospective 
cohort  
N=23,807; 
77±11.6 
 
Registry 
based 
Payer  1 year Unspecified Top-down 
approach**  
71 
15 Wang 201525 USA, High-
income 
economy 
Private 
Health 
System 19 
Retrospective 
cohort 
n=2,407; 
57.4 
 
Registry 
based  
Insurance 
(unspecified) 
3 years Unspecified Insurance 
claim data 
(unspecified) 
67 
16 Yiin 201458 UK, High-
income 
economy 
National 
Health 
Service 19 
Single-arm 
prospective  
n=383; 
80.0 ±9.7 
 
Registry 
based  
Institutional 
(unspecified) 
5 years 3.5% per 
year 
Bottom-up 
approach* 
74 
* Bottom-up approach based on national reference, medical chart review and/or physician and patients’ questionnaire interview for unit cost estimation as reported; ** Top-
down approach based on Diagnosis Related Groups (DRGs) or International Classification of Diseases (ICD) for overall cost estimation as reported; *** Mixed approach used 
two or three combinations of bottom-up approach, top-down approach and insurance claim data as reported.  
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Table 3. Ischemic stroke related cost by country income groups* 
Income group Direct costs (n=15) Indirect costs (n=3) Total costs (n=15) 
HIE (n=13) 40,730±19,623 4,487±5,275 41,420±19,485 
UMIE (n=1) 8,302 4,593 12,895 
LMIE (n=1) 8,184 - 8,184 
Overall (n=15) 36,398±21,464 4,522±3,730 37,302±21,078 
*Cost data were presented as I$ per patient based on IMF PPP values of 2015; 
HIE: high-income economies; UMIE: upper-middle income economies; LMIE: lower-middle income 
economies. 
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Table 4. Cost differences of patients with/without ischemic stroke 
Study no. Country  
(reported year) 
Per patient cost of 
AF only (mean±SD) 
Per patient cost of 
AF with ischemic 
stroke 
 
Cost increase 
(%)* 
5 USA (2007) $35,474±41,875 $63,781±48,422 80% 
9 UK (2009) £2,566±6,586 £3,370±7,156 31% 
11 USA (2006) $15,718±36,842 $43,937±49,568 180% 
12 USA (2011) $17,980 $51,605 187% 
* Cost increase (%) = 
𝑝𝑒𝑟 𝑝𝑎𝑡𝑖𝑒𝑛𝑡 𝑐𝑜𝑠𝑡 𝑜𝑓 𝐴𝐹 𝑤𝑖𝑡ℎ 𝑖𝑠𝑐ℎ𝑎𝑒𝑚𝑖𝑐 𝑠𝑡𝑟𝑜𝑘𝑒−𝑝𝑒𝑟 𝑝𝑎𝑡𝑖𝑒𝑛𝑡 𝑐𝑜𝑠𝑡 𝑜𝑓 𝐴𝐹 𝑜𝑛𝑙𝑦
𝑝𝑒𝑟 𝑝𝑎𝑡𝑖𝑒𝑛𝑡 𝑐𝑜𝑠𝑡 𝑜𝑓 𝐴𝐹 𝑜𝑛𝑙𝑦
 × 100% 
AF: atrial fibrillation 
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Figure 1. PRISMA flowchart 
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Figure 2. Study perspectives and costing approaches for 15 included cost analyses 
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Figure 3. Breakdown of direct cost from seven studies 
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Figure 4. Scatterplot of converted direct cost per patient and GDP per capita (I$ 2015) 
A: Scatterplot of converted direct cost per patient and GDP per capita (in all countries) 
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B: Scatterplot of converted direct cost per patient and GDP per capita (Exclusion of India and 
China) 
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Figure 5. Direct cost per patient in different healthcare systems 
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